The famous quote “Those who fail to learn from history are doomed to repeat it” seems appropriate when describing the pharmaceutical industry, at least according to our track record over the last few decades. It often feels like Groundhog Day, and we are Bill Murray hitting the alarm clock before realizing “Oh, here we go again!”
Medidata and INC Research co-hosted two seminars in California last week, featuring speakers from both companies as well as Halloran Consulting Group president Laurie Halloran. Following the seminars, Medidata’s John Vlachos spoke with colleagues Fran Nolan, vice president of quality and regulatory affairs, and Stephen Young, senior product director, about the future of clinical site monitoring and how the industry is rapidly moving towards implementing a risk-based approach.
Steve Young and I recently had the opportunity to represent Medidata at a joint INC Research and Medidata Solutions seminar on risk-based monitoring, held in beautiful Cambridge, Massachusetts. You can refer to a video blog recorded at the conclusion of the seminar to hear more about our general thoughts on the event.
Following a joint seminar with Medidata Services Partner INC Research, John Vlachos speaks with colleagues Fran Nolan, vice president of quality and regulatory affairs, and Stephen Young, senior product director, on how risk-based monitoring can help reduce site monitoring costs. Fran and Steve share insight on how sponsors and contract research organizations (CROs) are leveraging technology to adopt a risk-based approach.
As a Medidata customer, I look forward each year to the Medidata User Group (MUG), which offers an annual discussion in the Americas (A-MUG), Europe (E-MUG) and Asia (J-MUG) to hundreds of clinical research professionals. As with Geeks Talk Clinical, the MUG is dedicated to creating a collaborative and mutually beneficial environment to learn about, examine and challenge the impact of technology on clinical development.